News of Note—Sun Pharma’s U.S. sales crash; Avista expands API capacity; Quotient Sciences buys CDMO

Sun Pharma reported lower U.S. sales and much lower profit as an unfavorable quarterly comparison made a difficult market even more challenging.

> Sun Pharma, India’s largest drugmaker, reported a 59% crash this week in its last quarter profit. It said U.S. sales were down 44%, dropping to $309 million, as generic drug pricing pressures depressed sales. Release | Financials homepage

> Avista Pharma Solutions has completed an expansion that doubled the API manufacturing capacity at its Longmont, Colorado, site as part of a $20 million upgrade package being made there. Release

> Nottingham, U.K.-based Quotient Sciences has acquired Reading, U.K.-based CDMO Pharmaterials to expand its formulation and manufacturing services footprint. Release